Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions

Opioid-use Disorder

Interventions

DRUG

Buprenorphine/naloxone

5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily

DRUG

Placebo

placebo sub-lingual tablet daily

Trial Locations (2)

ACTIVE_NOT_RECRUITING

Stars/Nyspi, New York

RECRUITING

Avery Road Treatment Center (ARTC), Rockville

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

New York State Psychiatric Institute

OTHER